Active substanceCocarboxylaseCocarboxylase
Similar drugsTo uncover
  • Cocarboxylase
    lyophilizate w / m in / in 
    Company DEKO, LLC     Russia
  • Cocarboxylase
    lyophilizate w / m 
  • Cocarboxylase
    lyophilizate w / m in / in 
  • Cocarboxylase
    lyophilizate w / m in / in 
  • Cocarboxylase-Ferein
    lyophilizate w / m in / in 
    BRYNTSALOV-A, CJSC     Russia
  • Cocarboxylase-Ellara®
    lyophilizate w / m in / in 
    ELLARA, LTD.     Russia
  • Cocarboxylase hydrochloride
    lyophilizate w / m in / in 
  • Dosage form: & nbsplyophilizate for the preparation of solution for intravenous and intramuscular administration
    Composition:

    Composition per 1 ampoule (3 ml):

    Cocarboxylase hydrochloride - 50.0 mg;

    Sodium carbonate - 8.0 mg.

    Description:

    Liofilizirovannaya dry porous hygroscopic mass of white color with a weak specific odor.

    Pharmacotherapeutic group:Metabolic means
    ATX: & nbsp

    A.11.D.A   Vitamin B1

    Pharmacodynamics:

    Cocarboxylase is a coenzyme of thiamine (vitamin B1), in the body phosphorylated with the formation of mono-, di- and triphosphate esters, is part of the enzymes that catalyze the carboxylation and decarboxylation of alpha-keto acids, pyruvic acid. Endogenous cocarboxylase is formed in the body from exogenous thiamin by phosphorylation, however, the properties of cocarboxylase do not fully correspond to the properties of thiamine and it can not be used for the prevention and treatment of hypo- and avitaminosis B1. Cocarboxylase improves the absorption of glucose, trophic nervous tissue, contributes to the normalization of the function of the cardiovascular system. Reduces the level of lactic and pyruvic acid in the blood (increasing the content of these acids leads to the development of acidosis and an acidotic coma).

    Indications:

    Cocarboxylase is prescribed in the complex therapy of hepatic and renal failure, diabetic precoma and coma, diabetic ketoacidosis, chronic heart failure and cardiac rhythm disturbances, peripheral neuritis.

    Children prescribe the drug for the same indications. In newborns, the drug is also used in complex therapy of conditions associated with hypoxia and acidosis, including asphyxia of newborns, hypoxic encephalopathy, circulatory insufficiency, pneumonia, sepsis.

    Contraindications:

    Hypersensitivity to the drug.

    Application during pregnancy and lactation.

    Pregnancy and lactation:

    Due to the insufficient number of studies, the drug should be given to pregnant and lactating women.

    Dosing and Administration:

    Kokarboksilazu injected intramuscularly or intravenously (struino or drip). The contents of the ampoule (50 mg) are dissolved immediately before injection into 2 ml of water for injection. With intravenous injection, the volume is adjusted to 10-20 ml, with dropwise administration up to 200-400 ml, adding a 0.9% solution of sodium chloride or a solution of dextrose.

    Adults

    With violations of the heart rate: 100-200 mg per day for 15-30 days.

    For chronic heart failure: 50 mg for 2 hours before the use of digitalis preparations 2-3 times a day.

    In diabetes (ketoacidosis, coma): the daily dose is 100 mg.

    In acute renal and hepatic insufficiency: intravenously strontium 100-150 mg 3 times a day or drip (previously dissolved in 5 % solution of dextrose) at 100-150 mg per day.

    With peripheral neuritis: intramuscularly at 50-100 mg per day for 1-1.5 months.

    Children - in / m, in / in (drip or jet): depending on the severity and clinical symptoms - 25-50 mg / day. The course of treatment is from 3-7 to 15 days. The newborn is injected / in slowly -10 mg / kg 1 time per day.

    Side effects:

    Allergic reactions are possible (hives, itching); when intramuscular injection - hyperemia, itching, swelling (at the injection site).

    Overdose:

    There is no information.

    Interaction:

    Kokarboksilaza enhances the effect of cardiac glycosides and improves their tolerability.

    Form release / dosage:

    Lyophilizate for the preparation of solution for intravenous and intramuscular injection 50 mg.

    Packaging:For 50.0 mg of active substance in ampoules of 3 ml. For 5 ampoules of the drug complete with 5 ampoules of water for injection of 2 ml are placed in a box of cardboard. In each box, attach instruction for use, scarifier (when packing ampoules with notches, rings and dots for dissection, scarifiers do not invest).
    Storage conditions:

    In the dark place at a temperature of no higher than 25 FROM.

    Keep out of the reach of children.

    Shelf life:

    3 years. Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:P N002635 / 01
    Date of registration:18.03.2010 / 27.12.2012
    Expiration Date:Unlimited
    The owner of the registration certificate:FARMSTANDART-UFAVITA, JSC FARMSTANDART-UFAVITA, JSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp30.01.2018
    Illustrated instructions
      Instructions
      Up